Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: Influence of insulin resistance and oxidative stress

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 44-53

  Doronzo, Gabriella ^a   Viretto, Michela ^a   Russo, Isabella ^a   Mattiello, Luigi ^a   Di Martino, Leonardo ^a   Cavalot, Franco ^a   Anfossi, Giovanni ^a   Trovati, Mariella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

CGMP; Insulin resistance; MAPK; Nitric oxide; Oxidative stress; PI3 K; PKG; Vascular smooth muscle cells; Zucker rats

Indexed keywords

8 BROMO CYCLIC GMP; ANTIOXIDANT; CYCLIC GMP; HYDROGEN PEROXIDE; KT 5823; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ZUCKER RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE DONORS; OXIDANTS; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, ZUCKER; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; SUPEROXIDES; TIME FACTORS; XANTHINE OXIDASE;

EID: 79955528930     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.019     Document Type: Article

References (30)

1. Moncada S., Higgs E.A. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006, 147(Suppl. 1):S193-S201.
2. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424.
3. Tsai E., Kass D.A. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009, 122:216-236.
4. Lincoln T.M., Cornwell T.L. Intracellular cyclic GMP receptor proteins. FASEB J 1993, 7:328-338.
5. Jonk A.M., Houben A.J.H.M., deJongh R.T., Sernè E.H., Schaper N.C., Stehouwer C.D.A. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology 2007, 22:252-260.
6. Potenza M.A., Addabbo F., Montagnani M. Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab 2009, E568-E577.
7. Anfossi G., Russo I., Doronzo G., Trovati M. Contribution of insulin resistance to vascular dysfunction. Arch Physiol Biochem 2009, 115(4):199-217.
8. Russo I., Del Mese P., Doronzo G., et al. Resistance to the nitric oxide/cyclic guanosine 5′-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress. Endocrinology 2008, 149:1480-1489.
9. Bergandi L., Silvagno F., Russo I., et al. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003, 23:2215-2221.
10. Doronzo G., Russo I., Mattiello L., Anfossi G., Bosia A., Trovati M. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur J Clin Invest 2004, 34:664-673.
11. Sheu M.L., Chao K.F., Sung Y.J., Lin W.W., Lin-Shiau S.Y., Liu S.H. Activation of phosphoinositide 3-kinase in response to inflammation and nitric oxide leads to the up-regulation of cyclooxygenase-2 expression and subsequent cell proliferation in mesangial cells. Cell Signal 2005, 17:975-984.
12. Culmsee C., Gerling N., Landshamer S., et al. Nitric oxide donors induce neurotrophin-like survival signaling and protect neurons against apoptosis. Mol Pharmacol 2005, 68:1006-1017.
13. Kuwabara M., Kakinuma Y., Ando M., et al. Nitric oxide stimulates vascular endothelial growth factor production in cardiomyocytes involved in angiogenesis. J Physiol Sci 2006, 56:95-101.
14. Størling J., Binzer J., Andersson A.K., et al. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 2005, 48:2039-2050.
15. Kim S.O., Xu Y., Katz S., Pelech S. Cyclic GMP-dependent and -independent regulation of MAP kinases by sodium nitroprusside in isolated cardiomyocytes. Biochim Biophys Acta 2000, 1496:277-284.
16. Rabkin S.W., Tsang M.Y. The action of nitric oxide to enhance cell survival in chick cardiomyocytes is mediated through a cGMP and ERK1/2 pathway while p38 mitogen-activated protein kinase-dependent pathways do not alter cell death. Exp Physiol 2008, 93:834-842.
17. Komalavilas P., Shah P.K., Jo H., Lincoln T.M. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 1999, 274:34301-34309.
18. Frisbee J.C., Delp M.D. Vascular function in the metabolic syndrome and the effects of skeletal muscle perfusion: lessons from the obese Zucker rat. Essays Biochem 2006, 42:145-161.
19. Doronzo G., Russo I., Mattiello L., Riganti C., Anfossi G., Trovati M. Insulin activates hypoxia-inducible-factor-1alpha in human and rat vascular smooth muscle cells via phosphatidyl-inositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia 2006, 49:1049-1063.
20. Jadhav S., Petrie J., Ferrell W., Cobbe S., Sattar N. Insulin resistance as a contributor to myocardial ischemia independent of obstructive coronary atheroma: a role for insulin sensitisation?. Heart 2004, 90:1379-1383.
21. Sernè E.H., de Jongh R.T., Eringa E.C., Ijzerman R.G., Stehouwer C.D.A. Microvascular dysfunction in obesity: a potential role in the metabolic syndrome. Hypertension 2007, 50:204-211.
22. Clark M.G. Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle. Am J Physiol Endocrinol Metab 2008, 295:E732-E750.
23. Natali A., Toschi E., Baldeweg S., et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006, 55:1133-1140.
24. Yang X., Yang C., Farberman A., et al. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth. Journal of animal science 2008, 86:E36-E50.
25. Serpillon S., Floyd B.C., Gupte R.S., et al. Superoxide production by NAD (P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 2009, 297:H153-H162.
26. Anfossi G., Russo I., Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009, 19:440-449.
27. Russo I., Del Mese P., Doronzo G., et al. Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. Clin Chem 2007, 53:1053-1060.
28. Russo I., Traversa M., Bonomo K., et al. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity 2010, 18:788-797.
29. Avogaro A., de Kreutzenberg S.V., Fadini G.P. Insulin signalling and life span. Pflugers Arch 2010, 459:301-314.
30. Förstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010, 459:923-939.